Viremia clinical trials
The registry lists 83 studies for Viremia across more than 10 countries. 12 are recruiting or about to start. Per ClinicalTrials.gov, last updated 2026-08-25.
Status
- Completed
- 43
- Status unknown
- 13
- Recruiting
- 8
- Terminated
- 8
- Withdrawn
- 3
- Not yet recruiting
- 3
Phase
- Phase 2
- 19
- Phase 1
- 15
- Phase 4
- 11
- Phase 3
- 2
- Early Phase 1
- 1
Where
- United States
- 29
- China
- 8
- Spain
- 7
- Canada
- 5
- Brazil
- 4
- United Kingdom
- 4
Who runs them
Atara Biotherapeutics (4) · Peking University People's Hospital (3) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Indiana University (2) · University Health Network, Toronto (2) · New Discovery LLC (2) · University of California, San Francisco (2) · University College, London (2)
Studies
Recruiting first, then most recently updated. Showing 50 of 83 — search for more.
- Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIVRecruitingNCT06999928Not applicable1 country
- Adaptability of an Undetectable = Untransmissible Model for HBVRecruitingNCT074490911 country
- Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral TherapyNot yet recruitingNCT070151641 country
- Efficacy and Safety of Low-dose IL-2 in SLE Patients With CMV ViremiaNot yet recruitingNCT06971913Phase 21 country
- Safety, Virological and Immunological Assessment of the Controlled Dengue Human Infection Model in Dengue-Immune Participants in Thailand (DHIT-Immune)Not yet recruitingNCT06908018Early Phase 1
- Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.RecruitingNCT06646562Phase 41 country
- Magnesium Injection Ensures Steroid Avoidance During Vaccine, Viremia or ImmunocompromiseRecruitingNCT058624541 country
- HCMV Breakthrough Infections During Letermovir ProphylaxisRecruitingNCT06339892Not applicable1 country
- Expansion of Virus-Specific Lymphocytes for Cell TherapyRecruitingNCT06011486Phase 11 country
- Optimizing a Bio-behavioral Intervention for Sustained Viral SuppressionRecruitingNCT05377463Not applicable1 country
- Real-world CMV Outcomes Among Kidney Transplant Recipients in BrazilEnrolling by invitationNCT062632181 country
- Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant RecipientsRecruitingNCT05432778Phase 21 country
- Metagenomic Sequencing for the Identification of Pathogens in Febrile Neutropenic PatientsTerminatedNCT06075888Not applicable1 country
- Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent VaccineCompletedNCT05691530Phase 11 country
- Differentiated Service Delivery for Pregnant and Postpartum Women Living With HIV and Their InfantsCompletedNCT06629753Not applicable1 country
- Congenital Heart Anomaly Risk in Maternal Enteroviral Infection and DiabetesCompletedNCT04769167Not applicable1 country
- Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIVCompletedNCT05845619Not applicable1 country
- CMV-specific Donor-derived T Lymphocytes for the Treatment of Recalcitrant CMV Infection in a Patient With Primary ImmunodeficiencyActive, not recruitingNCT07015801Not applicable1 country
- Safety and Tolerability of AAV8 Delivery of a Broadly Neutralizing Antibody in Adults Living With HIV: a Phase 1, Dose-escalation TrialActive, not recruitingNCT03374202Phase 11 country
- Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney TransplantationTerminatedNCT05511779Phase 21 country
- Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)TerminatedNCT03769467Phase 1/21 country
- Clinical Performance Evaluation of the NeuMoDx™ EBV Quant Assay 2.0 in Immunocompromised Transplant PatientsCompletedNCT066810251 country
- Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T CellsTerminatedNCT03798301Phase 11 country
- Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT02136797Phase 21 country
- A Study to Evaluate the Antiviral Activity and Safety of HH-003 in Chronic Hepatitis B Subjects With Low-level ViremiaCompletedNCT05734807Phase 21 country
- Genotype-Informed Versus Empiric Management of VirEmiaCompletedNCT04233242Not applicable2 countries
- Study of Posoleucel (Formerly Known as ALVR105; Viralym-M) in Kidney Transplant Patients With BK ViremiaCompletedNCT04605484Phase 21 country
- Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV ViremiaWithdrawnNCT05700630Phase 11 country
- A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable ViremiaCompletedNCT02542852Phase 21 country
- Monitored Antiretroviral Pause in Chronic HIV-Infected Subjects With Long-Lasting Suppressed ViremiaCompletedNCT03198325Not applicable1 country
- Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted PatientsCompletedNCT04018261Phase 1/21 country
- Early Detection of Epstein-Barr Virus Related Disease.CompletedNCT035461011 country
- Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation RecipientsCompletedNCT044784741 country
- The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir TreatmentStatus unknownNCT057557761 country
- Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or MalignanciesNo longer availableNCT02822495
- A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant RecipientsCompletedNCT04294472Phase 22 countries
- Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived InfectionsStatus unknownNCT05799716Phase 4
- Therapeutic Vaccine Based on aDC1 Dendritic Cells for the Control of Viremia After ATI in HIV Infected IndividualsStatus unknownNCT05786937Phase 11 country
- Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or MalignanciesCompletedNCT00002663Phase 1/21 country
- Effectiveness of Intensive Adherence Counselling Among People Living With HIV/AIDS With Low-level Viraemia in Uganda.Status unknownNCT05514418Not applicable1 country
- Validation of a Proteomic Signature and Assessment of Viremia in Children With Fever Without SourceCompletedNCT032240261 country
- Cell-Mediated Immunity Based Primary Prophylaxis for CMV Infection in Organ Transplant RecipientsCompletedNCT02784756Not applicable2 countries
- "Switch Either Near Suppression Or THOusand"CompletedNCT03088241Not applicable1 country
- Peginterferon Alpha-2b Therapy in Chronic Hepatitis Patients With Normal ALT Level and Low ViremiaStatus unknownNCT05203055Phase 1/21 country
- Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV InfectionCompletedNCT00000790Phase 22 countries
- Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT03343834Not applicable1 country
- IVIg to Treat BK Viremia in Kidney Transplant RecipientsCompletedNCT02659891Phase 11 country
- Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus ViremiaWithdrawnNCT03532035Phase 23 countries
- CMV Infection and Immune Intervention After TransplantationStatus unknownNCT04320303Not applicable1 country
- Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT01646645Phase 21 country